• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Dextromethorphan and Quinidine for Treatment of Pseudobulbar Affect (PBA): Time Course of PBA Episode Remission (S31.007)
Conclusions: Approximately half of patients receiving DMQ-20 experienced PBA episode remission during this 12-week pivotal trial. Significant differences vs. placebo in the percentage of patients entering remission emerged early (Week 1) and remained significant in subsequent trial weeks.Study Supported by: Avanir Pharmaceuticals, Inc.Disclosure: Dr. Formella has received personal compensation for activities with Avanir Pharmaceuticals Inc. as an employee. Dr. Brooks has received personal compensation for activities with Biogen Idec, Avanir Pharmaceuticals, Acorda Therapeutics, Cytokinetics, Synapse, and the National Insti...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Formella, A., Brooks, B. Tags: General Neurology I Source Type: research

Amyotrophic Lateral Sclerosis Quality Measures (S46.006)
CONCLUSIONS: The AAN ALS quality measures, when implemented by providers, have the potential to significantly improve care for individuals with ALS.Study Supported by:Disclosure: Dr. Miller has received personal compensation for activities with Celgene, Pharmacyclic, Teva Neuroscience, and Taiji. Dr. Brooks has received personal compensation for activities with Biogen Idec, Avanir Pharmaceuticals, Acorda Therapeutics, Cytokinetics, Synapse, and the National Institute of Neurological Disorders and Stroke. Dr. Brooks has received research support from Biogen Idec, Avanir Pharmaceuticals, Cytokinetics, Neuraltus Pharmaceutica...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Miller, R., Brooks, B., Swain-Eng, R., Basner, R., Carter, G., Casey, P., Cohen, A., Dubinsky, R., Forshew, D., Jackson, C., Kasarskis, E., Procaccini, N., Sanjak, M., Tolin, F. Tags: Neuromuscular Disease: Genetics, Pathogenesis, and Measures Source Type: research

Emerging Subspecialties in Neurology: Palliative care
As we work to find cures for so many devastating neurologic injuries and diseases, our patients suffer tremendously on a daily basis. Individuals with conditions including stroke, multiple sclerosis, Parkinson disease (PD), muscular dystrophies, amyotrophic lateral sclerosis (ALS), and nervous system malignancies share a host of physical, emotional, and existential symptoms that can be difficult to treat. In addition, patients and their families face the realities of loss of function, loss of ability to communicate, and lifespans limited by the neurologic diagnosis or complications related to it (e.g., dysphagia, immobilit...
Source: Neurology - February 17, 2014 Category: Neurology Authors: Dallara, A., Tolchin, D. W. Tags: All Clinical Neurology, All Education, Palliative care RESIDENT AND FELLOW SECTION Source Type: research

Chronic over‐expression of TGFβ1 alters hippocampal structure and causes learning deficits
Abstract The cytokine Transforming Growth Factor β1 (TGFβ1) is chronically upregulated in several neurodegenerative conditions, including Alzheimer's disease, Parkinson's disease, Creutzfeldt‐Jacob disease, amyotrophic lateral sclerosis and multiple sclerosis, and following stroke. While previous studies have shown that TGFβ1 may be neuroprotective, chronic exposure to elevated levels of this cytokine may contribute to disease pathology on its own. In order to study the effects of chronic exposure to TGFβ1 in isolation we used transgenic mice that over‐express a constitutively active porcine TGFβ1 in astrocytes. W...
Source: Hippocampus - June 27, 2013 Category: Neurology Authors: Alonso Martinez‐Canabal, Anne L. Wheeler, Dani Sarkis, Jason P. Lerch, Wei‐Yang Lu, Marion S. Buckwalter, Tony Wyss‐Coray, Sheena A. Josselyn, Paul W. Frankland Tags: Research Article Source Type: research

TREM2 in neurodegeneration: evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson¿s disease
Conclusions: Our results suggest that the TREM2 p.R47H substitution is a risk factor for frontotemporal dementia and Parkinson’s disease in addition to Alzheimer’s disease. These findings suggest a more general role for TREM2 dysfunction in neurodegeneration, which could be related to its role in the immune response.
Source: Molecular Neurodegeneration - June 21, 2013 Category: Neurology Authors: Sruti RayaproluBianca MullenMatt BakerTimothy LynchElizabeth FingerWilliam SeeleyKimmo HatanpaaCatherine Lomen-HoerthAndrew KerteszEileen BigioCarol LippaKeith JosephsDavid KnopmanCharles WhiteRichard CaselliIan MackenzieBruce MillerMagdalena Boczarska-Je Source Type: research

TREM2 in neurodegeneration: evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson's disease
Conclusions: Our results suggest that the TREM2 p.R47H substitution is a risk factor for frontotemporal dementia and Parkinson's disease in addition to Alzheimer's disease. These findings suggest a more general role for TREM2 dysfunction in neurodegeneration, which could be related to its role in the immune response.
Source: Molecular Neurodegeneration - June 21, 2013 Category: Neurology Authors: Sruti RayaproluBianca MullenMatt BakerTimothy LynchElizabeth FingerWilliam SeeleyKimmo HatanpaaCatherine Lomen-HoerthAndrew KerteszEileen BigioCarol LippaKeith JosephsDavid KnopmanCharles WhiteRichard CaselliIan MackenzieBruce MillerMagdalena Boczarska-Je Source Type: research

PRISM Registry: A Novel Tool To Estimate the Prevalence of Pseudobulbar Affect Symptoms (P03.215)
CONCLUSIONS: PRISM provides novel insight into PBA symptom prevalence by prospectively evaluating a large number of patients across diagnoses and clinical settings. Follow-on studies are planned.Supported by: Avanir Pharmaceuticals, Inc.Disclosure: Dr. Brooks has received personal compensation for activities with Biogen Idec, Avanir Pharmaceuticals, Acorda Therapeutics, Cytokinetics, Synapse, and the National Institute of Neurological Disorders and Stroke. Dr. Brooks has received research support from Biogen Idec, Avanir Pharmaceuticals, Cytokinetics, Neuraltus, GlaxoSmithKline, Inc., and the National Institute of Neurolog...
Source: Neurology - February 14, 2013 Category: Neurology Authors: Brooks, B., Crumpacker, D., Fellus, J., Kantor, D., Kaye, R. Tags: P03 Multiple Sclerosis: Quality of Life and MS Symptoms Source Type: research

Neural stem cell‐based treatment for neurodegenerative diseases
Human neurodegenrative diseases such as Parkinson's disease (PD), Huntington's disease (HD), amyotrophic lateral sclerosis (ALS) and Alzheimer's disease (AD) are caused by a loss of neurons and glia in the brain or spinal cord. Neurons and glial cells have successfully been generated from stem cells such as embryonic stem cells (ESCs), mesenchymal stem cells (MSCs) and neural stem cells (NSCs), and stem cell‐based cell therapies for neurodegenerative diseases have been developed. A recent advance in generatioin of a new class of pluripotent stem cells, induced pluripotent stem cells (iPSCs), derived from patients' own sk...
Source: Neuropathology - February 1, 2013 Category: Neurology Authors: Seung U. Kim, Hong J. Lee, Yun B. Kim Tags: Review Article Source Type: research

Pages: 1  2  3  4  5  6  7  8  9  10  11